https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/news

The Latest

lab testing

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

blue pills on blue background

This Week in HIV Research: PrEP Relief

Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.

long winding road through countryside

This Week in HIV Research: The Long Road to the End

Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.

Actor Jonathan Del Arco portrays a Borg in a 1987 episode of Star Trek: The Next Generation

This Week in HIV Research: Resistance (Testing) Is Futile

Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.

Timothy Ray Brown at the Association of Nurses in AIDS Care (ANAC) in Portland, Oregon

The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"

Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.

Scientist holding slide with blood sample in lab

This Week in HIV Research: U=U Grows Ever Stronger

Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.

young man looking at pill before taking it

FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women

The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.

people in a doctor's office waiting room

This Week in HIV Research: The Reality of Disparity

Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.

woman with doctor looking at prescription bottle

This Week in HIV Research: Every Prescription Can Use a Good Steward

Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.

woman's hand dangling keys

This Week in HIV Research: New Keys to the Care Continuum

Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.